Investors & News

10/2022 | Businesswire

TLS Announces Partnership with HDX for BNCT in South Korea

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with HDX Corporation (HDX) to bring TLS’s targeted radiation therapy to South Korea for the treatment of difficult-to-treat cancers, such as brain, head and neck cancers and melanoma.

9/2022 | Business Wire

TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness

TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the publication of a study in the September 22 issue of the Journal of Medical Physics that assessed whether alpha particles generated through the combination of boron target drugs and proton radiation would generate a reaction that would be sufficient to enhance the biological effectiveness of proton therapy in the treatment of prostate cancer.

10/2021 | Business Wire

TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting

The session, “New Era in Biologically-Targeted Radiation Therapy: Clinical Application and Technical Advancement in Boron Neutron Capture Therapy” will feature presentations by Timothy Malouff, M.D., Mayo Clinic, Ester Orlandi, M.D., National Center of Oncological Hadrontherapy (CNAO) and Kendall Morrison, Ph.D., Chief Scientific Officer, TAE Life Sciences. They will discuss the clinical application and technical advancements in BNCT for the treatment of invasive, recurrent and difficult to treat cancers.

TLS in the News

Events

Developing targeted drugs for boron neutron capture therapy to treat refractory cancers

Developing targeted drugs for boron neutron capture therapy to treat refractory cancers

TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.

VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy

VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy

Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor.

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

RaySearch and TAE Life Sciences Announce Agreement on RayStation Support for the Alphabeam System for BNCT

BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.

$30M for Cancer-Focused TAE Life Sciences

$30M for Cancer-Focused TAE Life Sciences

HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Tiny Yet Mighty: Nanotechnology in Radiation Therapy

Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

New TAE Unit Launched To Treat Cancers Gains $40M In Financing And Closes Partnership Deal

BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences Inks $40M Series A Funding

TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences Raises $40M For Neutron Beam Cancer Treatment

TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.

TAE Raises $40M To Develop New Targeted Radiotherapy

TAE Raises $40M To Develop New Targeted Radiotherapy

Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.

$40 Million for Boron Neutron Capture Therapy

$40 Million for Boron Neutron Capture Therapy

TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.

A Surprise Application To Cancer

A Surprise Application To Cancer

There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

TAE Life Sciences Is Trying To Make Boron Neutron Capture Therapy More Accessible

The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.